BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  MC10 Enters Strategic Collaboration With LabCorp, Including Equity Investment, to Advance Clinical Trial Innovation and Healthcare Diagnostics

  As part of the collaboration, LabCorp has also made an equity investment into MC10.

  November 1, 2017

   · 

  3 min read
• Genetown

  Unum Therapeutics Announces Presentation of Initial Clinical Data from the ATTCK-20-2 Trial and Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the Upcoming 59th ASH Annual Meeting

  The oral presentation will highlight early data from an ongoing Phase I dose escalation study, ATTCK-20-2 (ClinicalTrials.gov No. NCT02776813), of ACTR087 used in combination with rituximab in subjects with relapsed/refractory CD20+ B cell Non-Hodgkin lymphoma.

  November 1, 2017

   · 

  5 min read
• Results of TherOx AMI Study for Improved Patient Outcomes Meets Primary Endpoint

  These results are included in the PMA application for the SSO2 Therapy system that has been accepted for filing by FDA

  November 1, 2017

   · 

  3 min read
• Business

  GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017

  GlycoMimetics announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results on Wednesday, November 8, 2017, at 8:30 a.m. ET.

  November 1, 2017

   · 

  1 min read
• Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug

  Jaguar Health announced today that its wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), has launched a significantly enhanced version of Mytesi.com, the website for Mytesi® (crofelemer),

  November 1, 2017

   · 

  3 min read
• BioMidwest

  Navidea to Present Late-Breaking Abstract at American College of Rheumatology Annual Meeting

  CSO of Navidea, will present a poster of an abstract, titled, “Evaluation of Intravenous Injection of Tc 99m Tilmanocept in Static Planar Gamma Emission Imaging and Fused SPECT/CT Imaging for Rheumatoid Arthritis” and provide an overview of Navidea’s development pipeline.

  November 1, 2017

   · 

  4 min read
• Genetown

  Magenta Therapeutics to Present Clinical Results and Preclinical Research at of ASH Annual Meeting

  Magenta Therapeutics announced that the Company will present clinical data from its stem cell expansion program and insights into its preclinical research at the 59th annual meeting of the ASH.

  November 1, 2017

   · 

  3 min read
• 

  Drug Development

  One-Time CAR-T Leader Juno Shows Off Promising New Clinical Data

  The company submitted 15 abstracts to be presented at the upcoming ASH Conference.

  November 1, 2017

   · 

  12 min read
• Pharm Country

  Alexion Release: New Phase I/II Study Data for ALXN1210 As a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at ASH Meeting

  Alexion Pharmaceuticals announced today that researchers will present new data from two Phase 1/2 clinical studies of ALXN1210.

  November 1, 2017

   · 

  12 min read
• Genetown

  Verastem Announces Data From Phase III DUO Study Selected for Oral Presentation at the ASH 2017 Annual Meeting

  Verastem focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that four abstracts have been selected for presentation, including two oral presentations, at the upcoming ASH 2017 Annual Meeting being held December 9-12, 2017 in Atlanta.

  November 1, 2017

   · 

  9 min read